Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

ADC oncology therapy market to value over $36b by 2029

0
SHARES

With antibody-drug conjugates (ADCs) gaining favour as oncology treatments, research shows Daiichi Sankyo, Seagen and Roche are currently three of the market’s most important players.

ADC oncology therapy market to value over $36b by 2029

According to research from GlobalData, the pharmaceutical industry is shifting towards development of antibody-drug conjugates (ADC) as oncology treatments.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The data showed that Daiichi Sankyo, Seagen and Roche are currently three of the most important companies in the ADC market. Daiichi Sankyo was predicted to remain the dominant player in this market.

Future of the antibody-drug conjugate therapy market

By 2029, the global market for ADC therapies in oncology is expected to be worth more than $36 billion, the research predicted. More investment in research and development is expected in the future, noted GlobalData.

Based on its market research, the firm forecasted major companies, including Astellas and AstraZeneca, achieving lower but still very profitable revenues compared to Daiichi and Seagen.

GlobalData’s analyst also shared that the company’s analysis revealed there are “almost 200 products in clinical trial Phases I, II, and III for different cancer types [in the ADC pipeline].”

ADC drugs are versatile and have “potential to change oncology care,” commented Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData. “Notably, HER2-positive breast cancer seems to be a major focus in this domain.”

ADC demonstrates meaningful survival data for HER2 cancers

Daiichi Sankyo’s recent trial results suggest that the company will continue to remain dominant in the oncology ADC market, the data and analytics company GlobalData stated.

In July 2023, high-level data from the TROPION-Lung01 Phase III trial of the ADC datopotamab deruxtecan, in previously treated advanced or metastatic non-small cell lung cancer (NSCLC), showed a statistically significant improvement in progression-free survival (PFS) compared to the standard treatment, docetaxel.

While antibody-drug conjugates have “clear benefits over current monotherapy and combination therapy options in cancer treatment”, Podder highlighted that current challenges include the potential for off-target toxicity, the development of drug resistance, as well as complex and costly manufacturing processes. Yet these treatments have clear potential, due to the market continuing to recognise their value, Podder concluded.

Pfizer to acquire Seagen for $43 billion

Share via
Share via